DETERMINAZIONE DEL DIRETTORE GENERALE

n. 300 DG del 23 LUG 2019

OGGETTO

APPROVAZIONE DELL'ACCORDO CON NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC PER LA CONDUZIONE DEL PROGETTO DI RICERCA DI CUI AL PROTOCOLLO DI STUDIO N. X-PDR001F/B3004206/IGB0.

Attestazione di legittimità e regolarità dell'istruttoria

Il dirigente della struttura semplice
Trasferimento Tecnologico (TTO)
(dott. Antonio Cannarozzo)

In base alle attestazioni rese dal dirigente competente all'adozione del provvedimento e alle verifiche contabili svolte:

☒ si provvede alle registrazioni contabili.
☐ il provvedimento non comporta registrazioni contabili, né impegni finanziari futuri.

Il dirigente della struttura complessa
Risorse Economiche e Finanziarie e Libera Professione
(dott. Giacomo Boscagli)

CON I PARERI FAVOREVOLI DEL		
Direttore Scientifico	**Direttore Amministrativo**	**Direttore Sanitario**
dott. Giovanni Apolone	dott. Andrea Frignani	dott. Oliviero Rinaldi

L'atto si compone di 12 (dodici) pagine di cui 9 (nove) pagine di allegati parte integrante
atti n. 1.6.05 - 322/2019
/ef

s.c. Affari Generali e Legali
IL DIRETTORE

FONDAZIONE IRCCS
Istituto Nazionale Tumori
VERCOL

IL DIRETTORE GENERALE

su proposta del Responsabile del procedimento della s.s. Trasferimento Tecnologico (TTO) che, a seguito di istruttoria, attesta:

visto il D. Lgs. n. 211/2003 in tema di "Attuazione della direttiva 2001/20/CE relativa all'applicazione della buona pratica clinica nell'esecuzione delle sperimentazioni cliniche di medicinali per uso clinico";

atteso che
- Novartis Institutes for Biomedical Research Inc., con sede legale in 250 Massachusetts Avenue, Cambridge, MA 02139, intende condurre un progetto di ricerca dal titolo "BRAF V600 testing to support a bridging concordance analysis for the Novartis COMBI-i (PDR001F2301) trial", protocollo di studio n. X-PDR001F/B3004206/IGB0, da svolgersi sotto la responsabilità scientifica del prof. Giancarlo Pruneri, Direttore della s.c. Anatomia Patologica 2;
- il progetto di ricerca di cui trattasi ha l'obiettivo di testare una serie rappresentativa di campioni di tessuto tumorale con diagnosi di melanoma per determinare il livello di sintonia tra il TEST THxID BRAF approvato dalla FDA e le analisi BRAF locali;
- le attività sopra menzionate verranno svolte su sezioni di 12 campioni esterni e trasmessi da Novartis alla Fondazione, per una durata fino al 23 dicembre 2019;

preso atto che in data 5 luglio 2019, il Direttore Scientifico della Fondazione ha rilasciato parere favorevole al progetto di ricerca;

preso atto del piano di spesa predisposto dal prof. Giancarlo Pruneri, pervenuto alla s.s. Trasferimento Tecnologico (TTO) in data 1 luglio 2019, nonché delle clausole economiche contenute nella convenzione di cui trattasi che prevedono:
- il pagamento da parte di Novartis Institutes for Biomedical Research Inc. di € 360,00 (oltre I.V.A se e in quanto dovuta) per ogni test di mutazione BRAF V600 da destinare alla s.c. Anatomia Patologica 2;
- pagamenti effettuati su base trimestrale, a fronte di emissione di regolare fattura;

dato atto che, il progetto di ricerca non è farmacologico e, pertanto, non necessita di stipulazione di alcuna polizza assicurativa *ad hoc* in quanto il medesimo trova ristoro nella polizza RCT/O;

considerato che la realizzazione di attività di ricerca sanitaria e la stipulazione dei correlati atti contrattuali rientrano nella missione e nelle finalità della Fondazione, in conformità alle disposizioni degli artt. 2 e 3 dello Statuto della Fondazione, approvato con Deliberazione del Consiglio di Amministrazione n. 12F del 2012;

s.c. Affari Generali e Legali
IL D[illegible]

ritenuto pertanto di approvare l'accordo di cui trattasi, precedentemente concordato con la s.s. Trasferimento Tecnologico (TTO), inoltrato da Novartis Institutes for Biomedical Research Inc., pervenuto in data 11 giugno 2019;

considerato che nulla osta alla pubblicazione del presente provvedimento in versione integrale all'Albo Pretorio della Fondazione, per 15 giorni consecutivi, ai sensi dell'art. 32 della L. n. 69/2009 e della L.R. n. 33/2009, nel testo vigente;

dato atto dell'attestazione di regolarità dell'istruttoria sia sotto il profilo tecnico che di legittimità, nonché delle disposizioni finanziarie e contabili;

richiamata la determinazione del Direttore Generale n. 311DG del 29 settembre 2017, avente ad oggetto "Disposizioni a carattere gestionale del Direttore Generale";

visti i pareri favorevoli dei Direttori Scientifico, Amministrativo e Sanitario della Fondazione resi per quanto di competenza,

D E T E R M I N A

1- di approvare l'accordo con Novartis Institutes for Biomedical Research Inc., con sede legale in 250 Massachusetts Avenue, Cambridge, MA 02139, nel testo allegato al presente provvedimento, di cui forma parte integrante e sostanziale, per la conduzione del progetto di ricerca da svolgersi sotto la responsabilità scientifica del prof. Giancarlo Pruneri, Direttore della s.c. Anatomia Patologica 2;
2- di dichiarare che l'importo relativo alle attività diagnostico-strumentali previste dal Protocollo di sperimentazione e meglio specificato in premessa verrà introitato sul conto n. 71101080 "Ricavi per prestazioni ambulatoriali da enti privati paganti", secondo la ripartizione indicata nel tariffario per le sperimentazioni cliniche approvato con determinazione 11 novembre 2014 n. 319DG nel testo vigente;
3- di individuare lo Sperimentatore Principale quale Direttore dell'Esecuzione del Contratto, con particolare riferimento alla corretta tempistica della fatturazione e al relativo monitoraggio, nonché quale persona autorizzata al trattamento dei dati oggetto della sperimentazione clinica in argomento;
4- di disporre la pubblicazione del presente provvedimento all'Albo Pretorio della Fondazione, per 15 giorni consecutivi, ai sensi dell'art. 32 della L. n. 69/2009 e della L.R. n. 33/2009, nel testo vigente.

per IL DIRETTORE GENERALE
dott. Stefano Manfredi

s.c. Affari Generali e Legali
Il Direttore

AGREEMENT

This Agreement ("**Agreement**") is entered into as of **Date of Last Signature** ("**Effective Date**") between Novartis Institutes for Biomedical Research, Inc., with an address at 250 Massachusetts Avenue, Cambridge, MA 02139 ("**Novartis**") and Fondazione IRCCS Istituto Nazionale Tumori, with an address at via Giacomo Venezian, 1 – 20133 Milan (Italy) ("**Institution**").

1. ACTIVITIES

1.1 Institution agrees to perform the activities described in **Annex A**, attached to this Agreement ("**Activities**") The project code is **X- PDR001F/B3004206/IGB0.**

1.2 The Activities shall be provided directly by Institution, under the scientific responsibility of prof. Giancarlo Pruneri, Head of s.c. Anatomia Patologica 2 of the Institution (the "Scientific Responsible").

1.3 Institution warrants that it shall provide the Activities (a) in accordance with the terms of this Agreement; (b) in a timely and professional manner, in conformance with that level of care and skill ordinarily exercised by other professionals in similar circumstances; (c) and in compliance with all applicable laws and regulations.

1.4 The parties shall regularly communicate about all relevant matters with regard to the Activities. Institution shall promptly inform Novartis about any unforeseen results, problems or difficulties with regard to the Services.

2. FEES & EXPENSES

2.1 In consideration of the Activities performed by Institution, Novartis agrees to pay to Institution the fees described in **Annex A.** In addition, Novartis will reimburse any reasonable expenses required to be incurred by Institution in connection with the Activities (such as for travel following Novartis travel policy and international courier charges), subject to production of receipts or other evidence of payment, all as pre-approved in writing by Novartis. Institution agrees that all of its pre-approved travel arrangements for the Activities shall be booked and ticketed through Novartis' travel department. However, the parties agree that travel in connection with the Activities shall be kept to a minimum, and that, where possible, telephone and/or video conferencing shall take priority.

2.2 Institution shall send applicable invoices to Novartis Institutes for Biomedical Research, Inc., PO Box 5990, Portland, OR 97228-5990, Tax ID 020567016. Institution shall itemize on the invoice Institution's name and address, the amount payable, bank details and the Novartis contact person, Aislyn Boran or such other person as may be designated by Novartis from time to time, as previously communicated by Novartis. Institution's Tax ID Number is IT04376350155.

2.3 The invoice sent to Novartis by Institution shall show one figure for the Activities plus a separate figure for expenses incurred by Institution in connection with the Activities since the last invoice. Receipts or other evidence of payment of the expenses must be sent to Novartis by the Scientific Responsible at the same time with the corresponding invoice. Except as specified in this Agreement, Institution will receive no other payments or reimbursements from Novartis for or in connection with the Activities. Institution hereby acknowledges and agrees that the fees paid under this Agreement are consistent with the Institution's applicable price list in arm's length transactions and that Institution's receipt of such fees is in full compliance with all applicable laws, rules, and regulations. Novartis reserves the right to

publicly disclose, in a time and manner of its choosing, the monies paid under this Agreement.

3. CONFIDENTIALITY

3.1 Institution undertakes to treat all scientific, technical, commercial and/or other information, data, documents and results provided by Novartis or otherwise obtained in connection with this Agreement ("**Information**") as confidential, except for Information which Institution demonstrates (a) was already in its possession at the time of disclosure; (b) is already generally available to the public, or subsequently becomes available without default of Institution; (c) is received by Institution from a third party who did not acquire it directly or indirectly from Novartis in confidence; or (d) is developed by Institution, independently from the Information disclosed. Nothing in Section 3 shall prevent the disclosure of those parts of the Information which are required to be disclosed by law or court order; provided, however, that Institution provides Novartis with prompt written notice of such requirement so that Novartis may seek a protective order or other appropriate remedy to prevent or limit such disclosure.

3.2 Institution will only use the Information for the purposes of this Agreement. After termination or expiry of this Agreement, Institution will return to Novartis or, at Novartis' option, will destroy any documents supplied by Novartis as well as all copies of and extracts from such documents; provided, however, that Institution may retain a copy for the sole purpose of verifying compliance with its obligations under this Agreement. The obligation set forth in Section 3 shall remain in effect during the term of this Agreement and for ten (10) years following the expiration or early termination of this Agreement.

4. INTELLECTUAL PROPERTY

4.1 All deliverables provided to Novartis in connection with this Agreement shall be owned by Novartis and Novartis (and its affiliates and collaborators) may use the deliverables for any purpose without any further obligation to the Institution or its employees or collaborators.

4.2 Intellectual property shall include without limitation all rights to and any interests in any patent, design, trade mark, copyright, know-how, trade secret and any other proprietary right or form of intellectual property (whether protectable by registration or not), customer list, specification, formula, device, drawing, design, system, process, logo or mark ("**Intellectual Property**"). All Intellectual Property provided to Institution by and/or on behalf of Novartis, in any form whatsoever, which is owned by or licensed to Novartis prior to being provided to Institution, shall remain the property of Novartis ("**Novartis Intellectual Property**"). Institution shall acquire no right, title or interest in the Novartis Intellectual Property as a result of its performance of the Activities.

4.3 Novartis shall be the owner of, and shall be entitled exclusively to use and commercially exploit at its sole discretion, all Intellectual Property conceived or reduced to practice by Institution or its collaborators in the course of the activities under this Agreement ("**Results**"). Institution hereby assigns transfers and conveys all its rights in and to the Results to Novartis. Institution and its collaborators shall, to the extent required, provide assistance and execute all documents that may be necessary for Novartis to obtain and secure Novartis' Intellectual Property rights in the Results.

4.4 Any Intellectual Property used by Institution in providing the Activities that: (a) existed prior to the Effective Date, or (b) are acquired by Institution from a third party or developed independently of the Activities, shall remain the property of Institution ("**Institution IP**"). .Institution hereby grants to Novartis a perpetual, world-wide, royalty-free, non-exclusive,

non-transferable irrevocable license to (and to permit its affiliates and customers to) use, execute, reproduce, transmit, display, perform, and create derivative works from any Institution IP incorporated into, made a part of or necessary for the use of any of the Results. The foregoing shall be subject to Novartis' payment of all undisputed amounts for the Activities that produced the applicable Results

4.5 Upon the request of Novartis, after completion of the Activities, or the early termination or expiration of this Agreement, Institution shall return to Novartis all Novartis Intellectual Property, and shall provide to Novartis all Results.

4.6 Anything in this Agreement to the contrary notwithstanding, Institution represents that it owns or has the right to use all rights to the Institution IP which it shall use to perform the Activities pursuant to this Agreement.

5. INDEMNIFICATION

5.1 Each Party shall indemnify, defend and hold the other Party (including all its officers, directors, employees, contractors and agents) harmless from and against any and all claims, demands, causes of action, damages, liabilities, losses, costs and expenses, including attorneys' fees (collectively, the "**Claims**"), arising out of, incident to, or resulting directly or indirectly from performance of the Agreement by that Party (including but not limited to its employees and sub-contractors), or from the breach by that Party of its warranties, representations, covenants and obligations save to the extent that such Claims arise out of the negligence, fraud, breach of contract or willful misconduct of that Party and/or its employees, subcontractors and/or agents.

6. TERM AND TERMINATION

6.1 This Agreement shall commence on the Effective Date and shall remain in force until December 23rd 2019 unless earlier terminated in accordance with this Section 6.

6.2 Novartis may terminate this Agreement upon written notice to Institution of at least thirty (30) days.

6.3 Either party may terminate this Agreement immediately at any time by written notice if the other party: (a) is in breach of any of its obligations under this Agreement and fails or is unable to remedy such breach within thirty (30) days of receipt of notice in writing specifying the breach; or, where applicable, (b) is or states that it is unable to pay its debts as they fall due, enters into any scheme of arrangement or composition with, or assignment for the benefit of all or any class or creditors, is wound up or has a liquidator, provisional liquidator, receiver and manager or statutory or other official manager appointed over all or any part of its property.

6.4 Upon the expiry or termination of this Agreement, Company shall discontinue the Services in the most cost effective manner possible.

6.5 If this Agreement is terminated (a) on notice in accordance with Section 6.2 then Novartis will remunerate Institution for costs incurred up to the termination and Institution will provide Novartis with all Results obtained up to termination; or (b) due to the breach of Institution in accordance with Section 6.3(a) then Novartis shall have no further obligations under this Agreement. Specifically Novartis shall not be liable to pay any fees or costs incurred by Institution under this Agreement.

6.6 Termination of this Agreement shall be without prejudice to any claim or right of action of either party against the other party for any prior breach of this Agreement. The provisions of

Section 3, Section 4, Section 6, Section 7 and Section 8 shall remain in force and effect notwithstanding the termination or expiration of this Agreement.

7. PUBLICATIONS AND PUBLICITY

7.1 Institution shall not make any publication, lecture, manuscript, poster presentation or other disclosure or dissemination (oral or written) containing Information or referring to the Activities or their Results, either during the term of this Agreement or after its termination or expiration, without the prior written approval of Novartis.

7.2 Neither party will use, or authorize others to use, the name, symbols, or marks of the other party in any advertising or publicity material or make any form of representation or statement with regard to the Activities which would constitute an express or implied endorsement by the other party of any commercial product or service without that other party's prior written approval. In particular, Institution shall not disclose that Novartis has retained Institution for professional services without the prior written permission of Novartis, not to be unreasonably withheld.

8. MISCELLANEOUS

8.1 **Assignment.** Neither Party may assign its rights and obligations under this Agreement without the other's written consent, except that Novartis, previous written communication to the Institution, may assign (a) its rights and obligations or any part to any of its Affiliates; or (b) this Agreement in its entirety to a successor to all or substantially all of its business or assets to which this Agreement relates. Any attempted assignment in contravention of the foregoing will be void. Subject to the terms of this Agreement, this Agreement will be binding upon and inure to the benefit of the parties and their respective successors and permitted assigns.

8.2 **Conflicting Obligations.** The parties covenant and represent that each of them has full right and authority to enter into this Agreement and to accept all the obligations under this Agreement, that they have no obligations with any third party which might be in conflict with this Agreement, and that they will during the term of this Agreement not enter into such obligations without the prior written consent of the other party.

8.3 **Corporate Citizenship.** Novartis gives preference to third parties who share its societal and environmental values, as set forth in the Novartis Corporate Citizenship Guideline (which can be found at http://www.novartis.com/downloads/about-novartis/Novartis_TP_Code.pdf) and incorporated by reference. Accordingly, Institution represents and warrants that this Agreement will be performed in compliance with all applicable laws and regulations, including without limitation, laws and regulations relating to anti-corruption and transparency.

8.4 **Debarment Certification** The Scientific Responsible and Institution agree that they are not and have not been debarred or disqualified from participating in clinical research by any United States regulatory authority or by any other regulatory authority, and that they will not use or involve any person or organization in connection with this Agreement that is or has been debarred or disqualified by any regulatory authority from participating in clinical research and observational study. In the event that Scientific Responsible and/or Institution or any person or organization they use or involve in connection with the Activities should become debarred or disqualified during the course of this Agreement, Scientific Responsible and/or Institution agree to promptly notify Novartis in writing

8.5 **Insurance.** Each Party warrants that it has appropriate and adequate insurance (including self insurance) to cover claims or damages for which it shall be liable under the terms of this Agreement. Upon demand by a Party, the other Party shall prove this insurance cover by furnishing to the requesting Party with an insurance certificate.

8.6 **Notices.** Any notice required or authorized to be served hereunder shall be deemed to have been properly served if delivered by hand, or sent by registered or certified mail, or sent by facsimile transmission confirmed by registered or certified mail, to the party to be served at the address specified by such party or, if no such address is specified, at the address given at the head of this Agreement. Notices sent by post shall be deemed to have been delivered within seven days after posting. Notices sent by facsimile shall be deemed to have been delivered within 24 hours of the time of transmission.

8.7 **Entire Agreement.** This Agreement represents the entire agreement and understanding between the parties relating to the subject matter of this Agreement, and supersedes any prior documents or verbal consents or understandings (if any) given or made between the parties. The terms of this Agreement may only be amended or modified by in writing signed by authorized representatives of the parties. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which, when taken together, shall constitute one and the same instrument.

8.8 **Waiver.** Neither party shall be deemed to have waived its rights under this Agreement unless such waiver is in writing and signed by such party. A waiver by a party of a breach of any provision of this Agreement by the other party shall not be deemed to be a waiver of any subsequent or continuing breach. Any delay or omission on the part of any party in the exercise of its rights will not impair those rights nor will it constitute a waiver of those rights. All rights, remedies, obligations and liabilities arising from this Agreement shall be cumulative and shall not be a limitation of any other right, remedy, obligation or liability.

8.9 **Force Majeure.** Neither party shall be liable to the other party for any failure to perform any obligation on its part hereunder to the extent that such failure is due to circumstances beyond its control which could not have avoided by reasonable diligence. The affected party shall notify the other party as soon as practicable of the occurrence of any such circumstance, and the parties shall meet to consider what steps, if any, can be taken to overcome any issues.

8.10 **Severability.** In the event any provision of this Agreement is held to be illegal, invalid or unenforceable, such provision shall be limited or eliminated to the minimum extent necessary and the remainder of this Agreement shall remain in full force and effect.

8.11 **Relationship.** Institution is an independent contractor and shall not act as a servant or agent of Novartis. Institution shall not be entitled to any benefits or compensation from Novartis except as set forth in this Agreement, and shall in no event be entitled to any fringe benefits payable to Novartis employees. Institution shall be solely responsible for meeting its tax requirements. Institution shall not make any representation on behalf of or bind Novartis to others in any manner.

8.12 **Headings and Annexes.** Headings in this Agreement are included for ease of reference only and have no legal effect. All Annexes to this Agreement shall form an integral part of this Agreement. With regard to any conflict between the terms of such Annexes and the terms of this Agreement, this Agreement shall govern.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

By: _____

Name: MATTHEW SQUIRES

Title: VP PRECISION MEDICINE

FONDAZIONE IRCCS ISTITUTO NAZIONALE TUMORI

By: _____

Name: dr. Stefano Manfredi

Title: General Manager

For acknowledgement and acceptance

By: _____

Name: prof. Giancarlo Pruneri

Title: Scientific Responsible

14 GIU 2019

S.C. Affari Generali e Legali
IL DIRIGENTE

ANNEX A

A. **Project Title:**

BRAF V600 testing to support a bridging concordance analysis for the Novartis COMBI-i (PDR001F2301) trial

B. **General Description**

Novartis to provide tissue samples for testing in RT-PCR with the EASY BRAF with the Diatech BRAF V600 mutation TEST by Institution, under the scientific responsibility of the Scientific Responsible. Results will be provided to Novartis via provision of completed requisition forms to Novartis-designated central lab.

C. **Activities and Timeframe**

Institution shall complete the following Activities in accordance with the following schedule:

Analysis of up to 12 samples provided to Institution by Novartis. 3 to 5 slides from each sample will be provided wherever possible. Complete analysis of all samples and provision of results to Novartis-designated central lab within 2 months after samples are received. Data queries should be resolved with 2 weeks of receipt. The project is anticipated to be 3 months in duration.

D. **Costs and payment schedule**

Description of Activity	Quantity	Unit Price (Euros €)	Local Currency (Euros €)	US $
BRAF (v-raf murine sarcoma viral oncogene homolog B1), gene analysis, V600 variant	12	€360	€4320	$4855
Total			€4320	US$ 4855

Payment schedule	In USD $
Upon Signature of the contract	[$2,428] (50% of total)
After all samples analyzed, data provided and data queries resolved	[$2,427] (50% of total)
Total	$4,855

In consideration of the Activities performed by Institution, Novartis agrees to pay to Institution a fee in the amount of USD $4,855 in total for handling, analysis and reporting on up to 12 samples. If invoices are unpaid by Novartis after 30 days of receipt an interest fee may be charged by Institution for the period of time past 30 days until the invoice is paid, at a rate of 8% per year (or rate as determined by law each semester). Unless otherwise agreed by Novartis in writing in advance, the maximum fees payable by Novartis under this Agreement amount to USD $4,855 excluding interest fees and expenses for returning any unused samples.

E. PROPOSAL FOR ACTIVITIES

This Statement of Work ("SOW"), shall form the basis of the Activities

Study Overview

Background and purpose: The purpose of this study is to test a representative set of melanoma tissue samples in a bridging concordance analysis required by FDA for COMBI-i trial registration. The bridging analysis will determine the level of concordance between the FDA-approved THxID® BRAF assay and local BRAF assay(s). The data will be submitted to FDA with the final study report.

Tumor tissue samples: Freshly cut FFPE slides for each melanoma tissue sample will be provided. Specimens will be provided by Novartis, are de-identified and with consent and permissions for further research, described herein.

Tissue samples must be stored at_ambient temperature at all times. Do not refrigerate or freeze.

Any tissue slides or blocks that remain after completion of BRAF testing will be returned to Novartis-designated central lab, unless otherwise specified.

Tumor tissue analysis: The analysis will be conducted under GCP with full protection of human subject practices.

The local BRAF V600 testing methodology used to determine the BRAF-status of sample must be provided with the tissue samples. This specifically includes:

- BRAF V600 test date
- BRAF V600 test result
- Commercial or lab-developed BRAF test name & manufacturer
- Testing methodology type (i.e., Sanger sequencing, real-time PCR, next-generation sequencing, etc.)

Data are requested to be provided to the Novartis-designated central lab in a largely unmodifiable report (e.g. PDF) containing, at a minimum, the sample/patient identifier provided on specimens, BRAF assay name and method and BRAF test result details. Queries will be issued by the Novartis-designated central lab for missing or incomplete information.

Novartis designated central lab: Navigate BioPharma Services, at 1890 Rutherford Road, Carlsbad, California, 92008, USA.

Remainder of page intentionally left blank.

9. CONTACT INFORMATION

(a) Client Partner Project Stakeholders:

All communication regarding sample logistics, requisition form completion, site provision of advance shipping notification, and data management should be directed to:

Name	Title	Phone	Email
Aislyn Boran	Precision Medicine Associate Director	+862-778-9475	aislyn.boran@novartis.com
Parul Patel	Biomarker Trial Manager	+18627789337	parul.patel@novartis.com

(b) Institution:

All communication regarding the Activities should be directed to:.

Name	Title	Phone	Email
Elena Tamborini	Biologist	+39-2-23902944	elena.tamborini@istitutotumori.mi.it
Federica Perrone	Biologist	+39-2-23902614	federica.perrone@ istitutotumori.mi.it

Remainder of page intentionally left blank.

s.c. Affari Generali e Legali
IL DIRETTORE